Biglycan may reduce muscle loss and liver cell aging related to getting older

To determine the age-related changes in BGN levels, we reanalyzed transcriptome data obtained from the Gene Expression Omnibus (GEO) database [12]. Analysis of the GSE175495 dataset revealed that BGN expression in skeletal muscle was significantly lower in older human subjects than in young subjects and that the expression of forkhead box O3 (Foxo3), which plays a pivotal role in muscle atrophy, was increased in older subjects (Figure 1A). In line with these results, the BGN level in human plasma gradually decreased with age, according to proteomic data reported by Lehallier et al. (Figure S1) [13]. In an aging mouse model, which was used in our previous study [14], the mRNA and protein expression of BGN was lower in the gastrocnemius (GA) muscle of aged mice than in that of young mice but was effectively rescued by exercise training (Figure 1B,C). We subsequently generated an accelerated aging mouse model using doxorubicin (Dox) (Figure 1D). The expression of senescence markers (p16 and p21), SASP markers (IL6, Ccl2, and Tgfβ1), and protein degradation-related genes (Foxo3, 4EBP1, and Atrogin) increased in the GA muscle of Dox-treated mice (Figure 1E), indicating the induction of senescence in muscle. Consistent with these findings, we observed a significant reduction in BGN levels in both the plasma and GA muscles of Dox-treated mice compared with control mice (Figure 1F,G). Collectively, these findings indicate that the expression of BGN, which serves as a myokine, is downregulated during aging but upregulated in response to exercise.

We subsequently assessed the expression and secretion of BGN during myogenesis, which is crucial for muscle formation, regeneration, and growth. During the differentiation of C2C12 myoblasts into myotubes, the expression of myogenin, myosin heavy chain (MyHC), and desmin, which are markers of myogenesis, increased upon the induction of differentiation. Similarly, the abundance of BGN increased on day 2 and gradually increased over 6 days during the process of myogenic differentiation (Figure 2A,B). Moreover, the secretion of BGN was greater in fully differentiated myotubes than in myoblasts (Figure 2C). To provide additional evidence of exercise-induced myokines, we analyzed BGN levels in myotubes following exercise-mimic stimulation. Fully differentiated myotubes were treated with forskolin (Fsk), which promotes cAMP pathway activation via the activation of adenylate cyclase activity. As anticipated, the mRNA expression of BGN and its level of secretion into the culture medium markedly increased after Fsk treatment (Figure 2D,E). These results suggest that BGN is released from mature myotubes and that BGN secretion increases in response to exercise stimulation.

Muscle atrophy is defined as a decline in muscle mass and function and is closely correlated with aging; thus, we next examined the effect of BGN on muscle atrophy. As observed in aged mice, dexamethasone (Dex), a glucocorticoid known to cause muscle atrophy by triggering the catabolism of muscle proteins, induced the expression of atrophy-related genes such as Atrogin and MuRF1, whereas the expression of BGN was significantly reduced in Dex-induced C2C12 myotube atrophy (Figure 3A). Importantly, biglycan treatment restored the thickness and length of myotubes impaired by Dex, as shown by MyHC staining (Figure 3B,C). Accordingly, BGN diminished the Dex-induced expression of muscle protein degradation-related genes, including Atrogin, myostatin (MSTN), 15-hydroxyprostaglandin dehydrogenase (Hpgd/15-PGDH), Krüppel-like factor 15 (Klf15), and Foxo3, in C2C12 myotubes (Figure 3D,E). These data indicate that BGN effectively alleviates Dex-induced muscle atrophy.

We then investigated the signaling mechanism through which BGN modulates muscle atrophy. Given that aging-related muscle atrophy results from increased muscle protein breakdown and decreased synthesis of new proteins [1], we hypothesized that BGN promotes protein synthesis. Since the AKT/mTOR pathway plays a key role in promoting protein synthesis in skeletal muscle, we assessed the activation of AKT/mTOR signaling. Western blot data revealed that the phosphorylation levels of serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR), 70-kDa ribosomal protein S6 kinase (p70S6K), and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), critical regulators of the translational machinery involved in protein synthesis, significantly increased in C2C12 myotubes treated with BGN (Figure 4A,B). Following these findings, we further examined the effect of BGN on protein synthesis rates and revealed increased puromycin incorporation into newly generated proteins under BGN-treated conditions (Figure 4C). Consistent with these findings, we observed a significant reduction in the phosphorylation levels of p70S6K and 4EBP1 after Dex treatment, whereas these adverse effects on muscle protein synthesis were abolished by treatment with BGN (Figure 4D). Collectively, these results demonstrate that BGN ameliorates muscle atrophy by promoting protein synthesis via activation of the AKT/mTOR axis.

During human aging, the liver undergoes various physiological and cellular changes that can increase susceptibility to liver damage and disease. Specifically, aging is associated with increased risk of liver diseases, including nonalcoholic fatty liver disease (NAFLD) and fibrosis [15]. Considering that BGN secretion decreases in older adults but increases through exercise, we next sought to determine whether BGN, as a myokine, plays a functional role in regulating the senescence of other metabolic tissues, especially the liver, beyond skeletal muscle. To this end, AML-12 cells, a normal mouse hepatocyte line, were treated with various doses of Dox, and 0.2 µM Dox was confirmed as an appropriate dose on the basis of cell viability (Figure 5A) as well as significant senescence-related changes in the expression of p21 and phosphorylated histone H2AX (γH2AX) (Figure 5B,C). Similarly, BGN treatment markedly decreased the number of SA-β-galactosidase-positive cells (Figure 5D,E) and suppressed the mRNA levels of p21, IL6, and TNFα, which are senescence-associated secretory phenotype (SASP)-related genes (Figure 5F), in Dox-treated hepatocytes. In addition, the protein level of p21 decreased, whereas that of the proliferation marker Ki67 was restored after treatment with BGN (Figure 5G). These findings indicate that BGN attenuates cellular senescence in hepatocytes.

Given that hepatocyte senescence is closely linked to intracellular lipid accumulation, we next evaluated the effect of BGN on aging-associated lipid accumulation in hepatocytes. BGN ameliorated hepatic triglyceride (TG) accumulation induced by palmitic acid (PA) and Dox in cells (Figure 6A,B). Consistent with these observations, the expression of lipogenic genes, including fatty acid translocase (FAT/CD36), glycerol-3-phosphate acyl-transferase (GPAT), and lipin1, was reduced in hepatocytes treated with BGN (Figure 6C). Oxidative stress is among the major mechanisms that lead to hepatic steatosis during aging [16]. In senescent cells, mitochondrial dysfunction continuously generates reactive oxygen species (ROS), which contribute to the impairment of metabolic function [17]. As expected, we observed elevated ROS levels in Dox-treated hepatocytes, but these changes were markedly reversed by BGN (Figure 6D,E). In accordance with the increase in oxidative stress, the expression of the antioxidant genes NAD(P)H quinone dehydrogenase 1 (Nqo1), heme oxygenase 1 (Hmox1), and catalase (CAT) decreased in Dox-treated cells (Figure 6F). These data suggest that the antisenescent effect of BGN on hepatocytes consequently attenuates aging-induced hepatic TG accumulation and oxidative stress.

Collectively, our results indicate that BGN expression is upregulated by exercise and acts in an autocrine manner to preserve muscle mass by enhancing protein synthesis via the AKT/mTOR pathway, thereby alleviating skeletal muscle atrophy. In the liver, BGN potentially plays a role in regulating cellular senescence, age-related lipid accumulation, and the SASP (Figure 7).

All mouse experiments and procedures were approved and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Korea National Institute of Health (permit numbers: KCDC-032-20-2A and KDCA-IACUC-24-030). The experimental procedures used for the aging mouse model have been thoroughly described previously [14]. Briefly, aged (18-month-old) C57BL/6 male mice (n = 10–12 per group) were randomly divided into 2 groups: a control group and an exercise group. The exercise intervention was performed 3 days a week for 4 months using a treadmill (Panlab, Cornellà de Llobregat, Spain). During the first week, the mice were allowed to adapt to the treadmill. After adaptation training, the mice were allowed to run at 5 m/min for 5 min and then at 13 m/min for 15 min/day 3 days a week for 4 months. For Dox-induced aging mouse experiments [32], a schematic diagram of the mouse model of Dox-induced aging is shown in Figure 1D. Eight-week-old male C57BL/6 mice were purchased from Kone Biotech (Seoul, Republic of Korea) and acclimatized for one week prior to the experiments. Dox was injected intraperitoneally at a dosage of 5 mg/kg every 3 days for 2 weeks, and PBS was injected as a negative control (n = 5 per group). After 2 weeks, the mice were euthanized, and the harvested tissues were frozen immediately. All the mice were maintained on a 12 h light/dark cycle under temperature- and humidity-controlled conditions and were allowed to acclimate for one week with free access to food and water.

C2C12 myoblasts (ATCC, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Waltham, MA, USA) and 1% penicillin/streptomycin (Gibco, Waltham, MA, USA). To induce myogenic differentiation, the growth medium was changed to DMEM supplemented with 2% horse serum (Gibco, Waltham, MA, USA) when the cells reached 80–90% confluence. AML12 mouse normal hepatocytes (ATCC, Manassas, VA, USA) were cultured in DMEM/F12 (Gibco, Waltham, MA, USA) supplemented with 10% FBS, 1% penicillin/streptomycin, 5 μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL selenium, and 40 ng/mL dexamethasone. Doxorubicin (Dox, D1515), dexamethasone (Dex, D4902), and palmitic acid (PA, P5585) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). BGN (8128-CM-050) was purchased from R&D Systems (Minneapolis, MN, USA).

Total RNA from cells or mouse skeletal muscle tissue was isolated using an RNeasy Mini Kit (QIAGEN, Germantown, MD, USA). Complementary DNA (cDNA) was transcribed from 2 µg of total RNA using SuperScript III Reverse Transcriptase (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA). Quantitative PCR (qPCR) was performed using SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) and a QuantStudio 6 Flex system (Thermo Fisher Scientific, Waltham, MA, USA). All the data were normalized to the expression of GAPDH, Hprt, or L32. The primer sequences are listed in Supplementary Table S1.

Cells and muscle tissue were homogenized in RIPA buffer supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Total protein was quantified using a BCA protein assay (Pierce; Thermo Fisher Scientific, Waltham, MA, USA), separated by electrophoresis on SDS–polyacrylamide gels, and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were subsequently blocked with 5% skim milk and probed with primary antibodies. Antibodies against BGN and γH2AX were obtained from Abcam (Cambridge, UK). Antibodies against AKT, phospho-AKT, mTOR, phospho-mTOR, S6 kinase (S6K), phospho-S6K, 4EBP1, phospho-4EBP1, S6, phospho-S6, Foxo3, p21, Ki67, and β-actin were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against MyoD, MyHC, Atrogin, and MuRF were purchased from Santa Cruz (Santa Cruz, CA, USA).

To assess BGN secretion from myoblasts and myotubes, the culture medium was changed with fresh serum-free medium. After a 1-h incubation, the medium was harvested and centrifuged at 1300 rpm for 5 min at 4 °C, and then the supernatant was collected. BGN levels were subsequently determined using a Mouse Biglycan ELISA Kit (Abcam, Cambridge, UK, ab275906) in accordance with the manufacturer's instructions.

Differentiated myotubes were fixed in 4% paraformaldehyde for 10 min and then were washed three times with PBS. After permeabilization with PBS containing 0.2% Triton for 5 min, the myotubes were blocked with 2% BSA for 1 h at 4 °C. The myotubes were subsequently incubated with an anti-Myosin 4 monoclonal antibody conjugated with Alexa Fluor 488 (1:200; Invitrogen, Waltham, MA, USA) in 0.2% BSA overnight at 4 °C. The next day, the myotubes were washed with PBS three times and incubated with DAPI. After five washes in PBS, images were acquired using a confocal microscope (Olympus, FV3000, Tokyo, Japan), and the diameter and length of the myotubes were quantified using ImageJ software, version 1.54p (NIH, Bethesda, MD, USA).

To evaluate protein synthesis in C2C12 myotubes, on day 5 of differentiation, the myotubes were treated with 1 µM puromycin for 1 h. Following treatment, the myotubes were harvested and subjected to Western blotting to detect puromycin-incorporated peptides.

AML12 cells were seeded at a confluence of 60% and treated with Dox with or without 1 μg/mL BGN pretreatment for 24 h at the concentrations indicated in the figure legend, and PBS was used as a negative control. After treatment, the cells were rinsed with PBS and stained to identify senescent cells using a commercial kit (Cell Signaling Technology, Danvers, MA, USA) in accordance with the manufacturer's protocol. Following staining, the cells were examined using a light microscope, and the β-galactosidase-positive areas were quantified with ImageJ software (NIH, Bethesda, MD, USA).

AML12 cells were seeded in 6-well plates and treated with 0.2 µM Dox and 200 µM PA for 24 h with or without 1 μg/mL BGN pretreatment. A 2% BSA solution was used as a negative control. After treatment, the cells were washed twice with PBS and stained with 10 µM DCFDA (Abcam, Cambridge, UK, ab113851) for 45 min at 37 °C. Following staining, the intracellular ROS levels were observed using a fluorescence microscope (Olympus, Tokyo, Japan).

All the data are presented as the means ± standard deviations (SD). Statistical analyses were performed using GraphPad Prism version 10 software (GraphPad, La Jolla, CA, USA). Comparisons between two groups were performed using Student's t test or the nonparametric Mann–Whitney U test. For multiple-group comparisons, we determined whether the data from each group followed a normal distribution using the Shapiro–Wilk test and the Kolmogorov–Smirnov test. In the case of normality, we performed a parametric one-way ANOVA with a Tukey post hoc test for multiple comparisons to assess the significance among pairs of conditions; in the case of nonnormality, we performed a Kruskal–Wallis test and a nonparametric post hoc test. For representative data, at least two independent experiments were performed to ensure reproducibility. Values of p < 0.05 were considered to indicate statistical significance.